

## Sun Pharma Laboratories Limited

Regd. Office : Sun House, Plot No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai - 400 063, Maharashtra, INDIA.  
Tel. : (91-22) 4324 4324  
Fax : (91-22) 4324 4343  
CIN : U25200MH1997PLC240268



**13<sup>th</sup> February, 2017**

General Manager  
BSE Limited.,  
Market Operations Dept.  
P. J. Towers,  
Dalal Street,  
Mumbai - 400 001.  
Scrip Codes: 953162 and 953164  
ISIN Nos: INE915T08016 and  
INE915T08024


Dear Sirs,

**Sub: Appointment of Mr. Kalyanasundaram Subramanian as an Additional Director and the Whole-time Director & Chief Executive Officer of the Company**

Pursuant to Regulation 51(2) read with PART B of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Board of Directors of the Company has appointed Mr. Kalyanasundaram Subramanian as an Additional Director of the Company with immediate effect. The Board of Directors of the Company have, further subject to the approval of the members of the Company at the ensuing General Meeting of the Company, appointed Mr. Kalyanasundaram Subramanian as the Whole-time Director & Chief Executive Officer of the Company for a period of two (2) years from February 13, 2017 to February 12, 2019. Mr. Kalyanasundaram Subramanian is not related to any of the Directors of the Company. Further, a brief profile of Mr. Kalyanasundaram Subramanian is enclosed herewith.

This is for your information and record.

Thanking you,

Yours faithfully,  
  
**For Sun Pharma Laboratories Limited**  
**Rachana Kokal**  
**Company Secretary & Compliance Officer**  
Encl: As above



**Mr. Kalyanasundaram Subramanian ('Kal')** joined Sun Pharmaceutical Industries Limited (SPIL) in January 2010 after 22 years with GSK in various parts of the world.

Kal is a Chemistry graduate and a Chartered Accountant from India with 37 years of experience of which some 30 years in the pharmaceutical industry.

Mr. Kal's career in Pharma industry began when he joined Burroughs Wellcome, in New Zealand as Commercial Advisor in 1988. His long and varied career with Burroughs Wellcome in New Zealand which was acquired by Glaxo to become GlaxoWellcome and finally GlaxoSmithKline, includes assignments as Vice President, head of Classic Brands business of Emerging Markets; Area Director South Asia & Managing Director, GSK India; Managing Director – GlaxoWellcome, Singapore (Singapore, Indochina & Myanmar). Commercial Director - Burroughs Wellcome, New Zealand.

In 2010, Kal Joined SPIL as the Chief Executive Officer to manage India and Emerging Markets (EM) and was a board member of SPIL. Kal was instrumental in Merck (MSD) and Sun collaboration and spearheaded opening of Sun operations in few important markets such as Japan, MENA.

In 2012, Kal moved to USA to assume responsibility for Taro operations in North America. In Jan 2017, Kal moved back to India to manage India and EM regions of Sun.